TABLE 2.
Platelet transfusion, bleeding, management practices, recurrent thrombosis data, and mortality outcome between preintervention and postintervention groups
| Before ISTH Guidance, N = 41 | After ISTH Guidance, N = 80 | P value | |
|---|---|---|---|
| Platelet transfusion per person, median (IQR) | 2.5 (1‐6) | 4 (2‐11) | 0.05 |
| Interruption or reduction in anticoagulation, n (%) | 24 (59) | 43 (54) | 0.70 |
| Hemorrhage, n (%) | 1 (2) | 13 (16) | 0.03 |
| Index VTE event <30 days | 0 (0) | 8 (18) | 0.10 |
| Index VTE event >30 days | 1 (2) | 5 (14) | 0.39 |
| Major bleed, a n (%) | 0 (0) | 6 (8) | 0.09 |
| Index VTE event <30 days | 0 (0) | 5 (14) | 0.31 |
| Index VTE event >30 days | 0 (0) | 1 (3) | >.99 |
| Platelet count (×103/µL) at time of hemorrhage, median (IQR) | 37 (‐) | 52 (35‐65) | … |
| Index VTE event <30 days | 0 (–) | 61 (39‐93) | … |
| Index VTE event >30 days | 37 (–) | 46 (12‐54) | … |
| Recurrent thrombosis, n (%) | 8 (20) | 6 (8) | 0.07 |
| Index VTE event <30 days | 2 (5) | 1 (1) | 0.17 |
| Index VTE event >30 days | 6 (15) | 5 (6) | 0.50 |
| Type of recurrence | 6–acute DVT | 2–acute DVT | … |
| 2–DVT progression | 1–DVT progression | ||
| 2–CRT | |||
| 1–VTE progression | |||
| Median platelet count at time of recurrence, median (IQR) | 63 (28‐97) | 76 (26‐176) | 0.75 |
| Time to recurrence [days (median, IQR)] | 20 (10‐37) | 40 (21‐110) | 0.17 |
| All‐cause mortality, n (%) | |||
| 30‐day | 5 (12) | 9 (11) | >.99 |
| 90 day | 8 (19) | 14 (18) | 0.81 |
Abbreviations: CRT, catheter‐related thrombosis; DVT, deep venous thrombosis; IQR, interquartile range; VTE, venous thromboembolism.
a
Major bleed = fatal bleeding and/or symptomatic bleeding into a critical area or organ, and/or bleeding causing a fall in hemoglobin of ≥2 g/dL or that requires transfusion of ≥2 units of whole blood or red cells.